Study study type PathologyT1T0Patientssample sizesROB Results

MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population

versus placebo
nivolumab alone
CheckMate 274 (all population), 2017
  NCT02632409
RCTMIBC - NA - all populationnivolumabplaceboadjuvant therapy patients with muscle-invasive high-risk urothelial carcinoma who had undergone radicalsurgery353 / 356low
conclusif
  • suggested 28 % decrease in RFS/DFS
  • demonstrated 30 % decrease in events or deaths (EFS) (PE)

MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive

versus placebo
nivolumab alone
CheckMate 274 (PDL1>1%), 2017
  NCT02632409
RCTMIBC - NA - PDL1 positivenivolumabplaceboadjuvant therapy patients with muscle-invasive high-risk urothelial carcinoma who had undergone radicalsurgery140 / 142low
conclusif
  • suggested 45 % decrease in RFS/DFS
  • demonstrated 45 % decrease in events or deaths (EFS) (PE)